CRBP logo

CRBP
Corbus Pharmaceuticals Holdings Inc

21,409
Mkt Cap
$178.43M
Volume
458,098.00
52W High
$20.56
52W Low
$6.10
PE Ratio
-1.69
CRBP Fundamentals
Price
$10.08
Prev Close
$10.06
Open
$10.06
50D MA
$9.13
Beta
1.25
Avg. Volume
226,272.78
EPS (Annual)
-$5.90
P/B
1.20
Rev/Employee
$0.00
$53.90
Loading...
Loading...
News
all
press releases
Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Crosses Above Fifty Day Moving Average - Should You Sell?
Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Above 50-Day Moving Average - Should You Sell...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded by Wall Street Zen to "Sell" Rating
Wall Street Zen raised shares of Corbus Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday...
MarketBeat·3d ago
News Placeholder
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the...
MarketBeat·20d ago
News Placeholder
Corbus Pharmaceuticals Holdings, Inc. $CRBP Stock Holdings Lifted by Aberdeen Group plc
Aberdeen Group plc lifted its position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 602.2% during the 4th quarter, according to the company in its most recent disclosure...
MarketBeat·20d ago
News Placeholder
Corbus Pharma Aligns With FDA On Registration Path For CRB-701 In HNSCC And Cervical Cancer
(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical-stage company, Tuesday announced that it broadly aligned with the FDA on the registration path for CRB-701, a highly stable Nectin-4 targeting ADC, in head and neck squamous cell carcinoma (HNSCC) and cervical c...
Nasdaq News: Markets·21d ago
News Placeholder
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Crosses Above 50-Day Moving Average - Time to Sell?
Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Pass Above 50 Day Moving Average - What's Next...
MarketBeat·1mo ago
News Placeholder
HC Wainwright Issues Negative Forecast for CRBP Earnings
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Research analysts at HC Wainwright dropped their Q1 2026 earnings estimates for shares of Corbus Pharmaceuticals in a research...
MarketBeat·2mo ago
News Placeholder
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%
The mean of analysts' price targets for Corbus Pharmaceuticals (CRBP) points to a 318.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·2mo ago
News Placeholder
Research Analysts Offer Predictions for CRBP FY2030 Earnings
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals...
MarketBeat·2mo ago
News Placeholder
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Expected to Rise, Oppenheimer Analyst Says
Oppenheimer boosted their price target on shares of Corbus Pharmaceuticals from $53.00 to $57.00 and gave the company an "outperform" rating in a research report on Tuesday...
MarketBeat·2mo ago
<
1
2
...
>

Latest CRBP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.